Why is Glaukos stock surging today?

Glaukos stock surged 15.8% in pre-open trading today after the company reported blowout third-quarter 2026 results the prior evening, with revenue of $211.03 million crushing the Wall Street consensus of $168.03 million by more than 25% and adjusted earnings per share of $0.47 dramatically reversing an expected loss of $0.10. The quarter marked a 58% year-over-year revenue increase, driven by record U.S. Glaucoma segment sales of approximately $119 million and U.S. Corneal Health revenue of $59 million — the latter surging roughly 154% year-over-year on the back of Epioxa, the company’s epi-on corneal cross-linking therapy, which alone generated $53 million in sales, well ahead of analyst models. Management also raised full-year 2026 net sales guidance to $775–$785 million from a prior range of $680–$700 million, and introduced a preliminary 2027 revenue target of $1 billion, with CEO Thomas Burns stating that results reflect "successful global execution across our key global commercial and development priorities, leaving us well positioned to sustain our strong growth momentum driven by two transformational growth drivers in iDose TR and Epioxa."

The earnings beat triggered a flurry of analyst activity today, amplifying the pre-market move. Mizuho raised its price target on the shares to $225 from $185 while maintaining an Outperform rating, citing Epioxa’s dramatic outperformance relative to estimates. Needham lifted its target to $251 from $201 (Buy), highlighting the company’s improving profitability trajectory and expanded Epioxa site-of-care network. Truist Securities also raised its target to $255 from $215, maintaining a Buy rating. The stock’s pre-market price of $210.10 represents a decisive break above its prior 52-week high of $191.62, reflecting a significant re-rating of the company’s growth profile.

The broader market backdrop today is a headwind rather than a tailwind for most stocks. Nasdaq futures were down roughly 1% in pre-market, pressured by Alphabet’s disappointing Q3 results — which missed revenue expectations and weighed on sentiment across the technology sector. The S&P 500 futures were also modestly lower. This makes Glaukos’s pre-market surge all the more striking, as it is advancing sharply against a risk-off tone driven by concerns over AI spending returns among large-cap tech names.

Taken together, the combination of a historic earnings beat, a massive guidance raise, a bold $1 billion preliminary 2027 revenue target, and a cascade of analyst price target increases created a powerful, company-specific catalyst that overwhelmed the negative macro backdrop. Glaukos’s two key commercial products — iDose TR and Epioxa — both demonstrated accelerating commercial traction, validating the long-term growth thesis and propelling the stock to levels well beyond its previous all-time high.